Bridge City Capital LLC Sells 7,235 Shares of LeMaitre Vascular, Inc. $LMAT

Bridge City Capital LLC trimmed its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 9.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 66,623 shares of the medical instruments supplier’s stock after selling 7,235 shares during the quarter. LeMaitre Vascular makes up 1.6% of Bridge City Capital LLC’s holdings, making the stock its 23rd largest holding. Bridge City Capital LLC’s holdings in LeMaitre Vascular were worth $5,403,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of LMAT. MAI Capital Management bought a new stake in LeMaitre Vascular during the 3rd quarter worth approximately $38,000. Geneos Wealth Management Inc. increased its stake in LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 398 shares in the last quarter. EverSource Wealth Advisors LLC bought a new stake in LeMaitre Vascular during the 2nd quarter worth approximately $47,000. GAMMA Investing LLC increased its stake in LeMaitre Vascular by 32.7% during the 4th quarter. GAMMA Investing LLC now owns 727 shares of the medical instruments supplier’s stock worth $59,000 after purchasing an additional 179 shares in the last quarter. Finally, Quarry LP increased its stake in LeMaitre Vascular by 267.2% during the 3rd quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock worth $64,000 after purchasing an additional 529 shares in the last quarter. 84.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently issued reports on LMAT. Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Citizens Jmp increased their target price on LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 6th. Barrington Research reissued an “outperform” rating and set a $120.00 target price on shares of LeMaitre Vascular in a research note on Wednesday, June 3rd. Roth Mkm reissued a “buy” rating and set a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday, February 26th. Finally, Weiss Ratings raised LeMaitre Vascular from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $112.60.

LeMaitre Vascular Trading Down 0.4%

NASDAQ:LMAT opened at $91.96 on Friday. LeMaitre Vascular, Inc. has a twelve month low of $79.00 and a twelve month high of $118.01. The company has a quick ratio of 12.20, a current ratio of 14.32 and a debt-to-equity ratio of 0.42. The business has a 50 day moving average price of $104.09 and a two-hundred day moving average price of $96.01. The company has a market cap of $2.10 billion, a P/E ratio of 33.93, a price-to-earnings-growth ratio of 2.55 and a beta of 0.54.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.02. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The firm had revenue of $66.55 million during the quarter, compared to the consensus estimate of $66.67 million. During the same quarter in the prior year, the firm posted $0.48 EPS. The business’s revenue was up 11.1% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. As a group, analysts expect that LeMaitre Vascular, Inc. will post 3 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Thursday, May 21st were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Thursday, May 21st. This represents a $1.00 dividend on an annualized basis and a yield of 1.1%. LeMaitre Vascular’s dividend payout ratio is 36.90%.

Insiders Place Their Bets

In other LeMaitre Vascular news, Director Bridget A. Ross sold 5,044 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $111.10, for a total transaction of $560,388.40. Following the completion of the transaction, the director owned 3,942 shares of the company’s stock, valued at $437,956.20. This represents a 56.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO George W. Lemaitre sold 27,881 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $108.69, for a total value of $3,030,385.89. Following the transaction, the chief executive officer directly owned 1,430,019 shares of the company’s stock, valued at approximately $155,428,765.11. This trade represents a 1.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 54,453 shares of company stock valued at $5,906,174 in the last quarter. 7.40% of the stock is currently owned by insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.